10-K: uniQure Faces Regulatory Hurdle for Huntington's Gene Therapy

uniQure N.V. reported positive topline data for its lead Huntington's disease gene therapy, AMT-130, but the FDA deemed the current Phase I/II data insufficient for a Biologics License Application (BLA) submission, recommending a randomized, double-blind, sham surgery-controlled study.

Summary

• uniQure N.V. is a gene therapy leader focused on rare and devastating diseases, with a pipeline including candidates for Huntington's disease (AMT-130), refractory mesial temporal lobe epilepsy (AMT-260), Fabry disease (AMT-191), and SOD1-ALS (AMT-162).
• AMT-130 for Huntington's disease showed statistically significant slowing of disease progression at 36 months in high-dose patients, with a 75% slowing by cUHDRS (p=0.003) and 60% by TFC (p=0.033), compared to an external control.
• Despite positive topline data and Breakthrough Therapy designation for AMT-130, the FDA stated in December 2025 and March 2026 that Phase I/II data are unlikely to support a BLA submission and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study.
• The company completed enrollment of the first cohort for AMT-260 in MTLE in 2025 and initiated enrollment for a second cohort.
• AMT-191 for Fabry disease showed sustained increases in α-Gal A enzyme activity across three dose cohorts, with six of 11 dosed patients withdrawn from ERT, but dosing in midand high-dose cohorts was paused due to asymptomatic Grade 3 liver enzyme elevations in two patients.
• Enrollment for AMT-162 in SOD1-ALS was voluntarily paused in September 2025 due to a dose-limiting toxicity and a serious adverse event (SAE) related to AMT-162 in one patient.
• uniQure completed two follow-on public offerings in January/February and September 2025, raising net proceeds of $80.5 million and $323.7 million, respectively.
• The company amended its loan facility with Hercules Capital, Inc. in September 2025, securing a $175.0 million senior secured term loan facility, with $50.0 million drawn and additional tranches contingent on BLA approval of AMT-130 and Hercules' approval.
• Net loss for the year ended December 31, 2025, was $199.0 million, an improvement from $239.6 million in 2024 and $308.5 million in 2023.
• As of December 31, 2025, cash, cash equivalents, and investment securities totaled $622.5 million, with an accumulated deficit of $1,328.9 million.
• The company expects existing cash resources to fund operations into the second half of 2029.
• A class action complaint was filed on February 10, 2026, alleging false and misleading statements regarding AMT-130's Phase I/II study and BLA timing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development due to the FDA's clear rejection of the current AMT-130 data for BLA submission and the recommendation for a costly, time-consuming Phase III study, which introduces substantial delays and uncertainty for the company's lead program. While capital was raised and other programs are advancing, the primary value driver faces a major setback, compounded by clinical holds/pauses on other candidates.

Positives

• AMT-130 for Huntington's disease demonstrated a statistically significant 75% slowing of disease progression by cUHDRS (p=0.003) and 60% by TFC (p=0.033) at 36 months in high-dose patients compared to an external control.
• Favorable trends were observed in other secondary endpoints for AMT-130, including an 88% slowing by SDMT (p=0.057) and 113% by SWRT (nominal p=0.002).
• AMT-130 received Breakthrough Therapy designation from the FDA in April 2025, in addition to previous RMAT, Orphan Drug, and Fast Track designations, indicating potential for substantial improvement over existing therapies.
• AMT-130 was generally well-tolerated with a manageable safety profile, and no new drug-related serious adverse events (SAEs) observed since December 2022.
• AMT-260 for MTLE showed a 92% reduction in seizure frequency in the first treated patient through five months of follow-up, with no serious safety events.
• AMT-191 for Fabry disease demonstrated sustained, dose-dependent increases in α-Gal A enzyme activity (0.34to 312.52-fold above mean normal range) across three dose levels, with durability observed for over a year in some patients.
• Six of 11 AMT-191 dosed patients were successfully withdrawn from enzyme replacement therapy (ERT) while maintaining stable plasma lyso-Gb3 levels.
• The company successfully raised significant capital through two follow-on public offerings in 2025, totaling $404.2 million in net proceeds.
• The Hercules loan facility was amended in September 2025, providing access to an additional $125.0 million, contingent on BLA approval for AMT-130 and Hercules' approval for the third tranche.
• Net loss decreased to $199.0 million in 2025 from $239.6 million in 2024 and $308.5 million in 2023, indicating improved financial performance.
• Cash, cash equivalents, and investment securities increased to $622.5 million as of December 31, 2025, from $367.5 million in 2024, extending the cash runway into the second half of 2029.

Negatives

• The FDA stated that data from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission, strongly recommending a prospective, randomized, double-blind, sham surgery-controlled study.
• Dosing in the midand high-dose cohorts for AMT-191 (Fabry disease) has been paused due to asymptomatic Grade 3 liver enzyme elevations observed in two patients, confirmed as dose-limiting toxicity.
• Enrollment for AMT-162 (SOD1-ALS) was voluntarily paused due to a dose-limiting toxicity and a serious adverse event (SAE) related to AMT-162 in one patient.
• The company incurred a net loss of $199.0 million in 2025 and has an accumulated deficit of $1,328.9 million as of December 31, 2025, indicating continued unprofitability.
• Collaboration revenue decreased significantly in 2025 by $10.7 million compared to 2024, primarily due to a reduction in services requested by CSL Behring following the Lexington Transaction.
• The company is subject to a class action complaint filed on February 10, 2026, alleging false and misleading statements regarding AMT-130 data and BLA timing.
• The availability of the $100.0 million second tranche of the Hercules loan is subject to BLA approval of AMT-130 prior to June 2027, and the third tranche of $25.0 million is subject to Hercules' approval, creating funding uncertainty.
• The company's reliance on external historical controls for AMT-130 data analysis was not accepted by the FDA as sufficient primary evidence of effectiveness for a marketing application.

Risks

• Dependence on the success of AMT-130; failure in clinical development, regulatory approval, manufacturing, or commercialization could adversely affect the business.
• Potential for future delays in clinical trials or failure to demonstrate safety and efficacy of product candidates.
• Early-stage clinical trial progress may not be predictive of long-term efficacy in late-stage trials, or for other product candidates.
• Inability to successfully commercialize product candidates or significant delays, including BLA delays or rejections, could materially harm the business.
• Approved gene therapies may fail to achieve market acceptance by physicians, patients, and third-party payers.
• Interim, topline, or preliminary clinical trial results may change as more data become available or due to regulatory audit/verification, leading to material changes in final conclusions.
• Uncertainty regarding when or if marketing approval will be obtained for product candidates.
• Disruptions or changes at the FDA or other government agencies could hinder timely guidance and approval of product candidates.
• Heightened risks in the marketing approval process due to products being gene therapies, with limited regulatory experience.
• Inability to obtain and maintain benefits associated with specialized regulatory pathways and designations (e.g., accelerated approval, RMAT, Breakthrough Therapy designation).
• Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception or affect business/approvals.
• Business development and strategic initiatives, acquisitions, partnerships, collaborations, or other transactions may not achieve intended benefits or goals and may result in additional risks.
• Inability to obtain rights from external parties to new product candidates and key technologies, or to secure partnerships.
• Gene therapies are complex, expensive, and difficult to manufacture; third-party manufacturers (like Genezen) could experience capacity, production, or technology transfer challenges.
• Manufacturing of products and candidates is subject to significant government regulations and approvals; reliance on third parties may lead to unsatisfactory performance or non-compliance.
• Continued net losses and potential inability to achieve or maintain profitability.
• Future changes in legal and regulatory requirements or standards may materially impact results of operations.
• Volatility and substantial fluctuation in the market price of ordinary shares.
• Dependence on ability to retain key executives, technical staff, and other employees and to attract, retain, and motivate qualified personnel.
• Substantial competition from other companies developing therapies for similar uses.
• Certain product candidates may require medical devices for administration and/or diagnostics, necessitating additional regulatory approvals and compliance.
• Data analyses based on post-hoc analyses, pooled data, or external historical controls may not be accepted as a basis for regulatory approval.
• Reliance on exploratory biomarkers and other non-validated data may lead to inefficient resource allocation.
• Inability to successfully use gene therapy technology platform to build a pipeline of additional product candidates or leverage research to remain competitive.
• The sale of the former manufacturing facility to Genezen may not yield expected benefits and could result in additional risks, including Genezen's ability to meet manufacturing requirements.
• Existing and future indebtedness could adversely affect the ability to operate the business.
• Relationships with employees, customers, and third parties are subject to laws and regulations, with non-compliance leading to material adverse effects.
• Subject to laws governing data protection and artificial intelligence (AI), with compliance failures potentially leading to penalties.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Healthcare legislative and regulatory reform measures may have a material adverse effect on financial operations.
• Future growth may depend on penetrating markets outside the U.S. and Europe, subject to additional regulatory burdens and risks.
• U.S. or other foreign judgments may be difficult to enforce against the company in the Netherlands.
• Non-compliance with all best practice provisions of the Dutch Corporate Governance Code may affect shareholder rights.
• Expected subjection to the Dutch large company regime may impact governance structure.
• Dutch and European insolvency laws may offer shareholders less protection than U.S. insolvency laws.
• Shareholders may not be able to exercise pre-emption rights, leading to substantial dilution upon future share issuances.
• Adverse effects from unstable market and economic conditions, including inflation, tariffs, and higher interest rates.
• Failure to maintain an effective system of internal controls could lead to inaccurate reporting or fraud.
• Internal computer systems or those of collaborators/vendors may fail or suffer security breaches, disrupting business and development programs.
• Inaccurate or unfavorable research by securities or industry analysts could cause share price and trading volume to decline.
• Failure to achieve projected development and financial goals in announced timeframes could delay commercialization and cause share price decline.
• Environmental sustainability and social initiatives may impose additional costs and expose the business to new risks.

Future Outlook

The company intends to continue engaging with the FDA regarding Phase III development considerations for AMT-130 and plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches. It expects existing cash and cash equivalents and investment securities to fund operations into the second half of 2029, with potential additional funding needed for late-stage development and commercialization of product candidates. The company also expects to become subject to the Dutch large company regime in August 2026, which will impact its governance structure.

Management Comments

• We believe that the consistently favorable results in functional, motor and cognitive endpoints at 36 months observed in the high-dose group, compared to the variable trends observed in the low-dose group, reflect a dose-dependent response to AMT-130.
• We intend to continue engaging with the FDA regarding Phase III development considerations and plan to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.
• Our mission is to deliver curative, one-time administered genomic medicines that transform the lives of patients. We aim to build an industry-leading, fully integrated, and global company that leverages its technology and proprietary manufacturing platform to deliver these medicines to patients with serious unmet medical needs.
• We believe that our advantages in vector and manufacturing technology will enable us to reach market in a number of indications ahead of our competitors, and to potentially capture the markets in these indications either by being first or in those markets with larger populations having a differentiated product.
• We believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, such statements are only predictions based on managements current views and assumptions and involve risks and uncertainties, and actual results could differ materially from those projected or implied.
• We believe that our facilities are adequate to meet current needs and that suitable additional or alternative spaces will be available in the future on commercially reasonable terms.
• Our management is responsible for establishing and maintaining adequate internal control over financial reporting and disclosure controls. Based on such evaluation, our CEO and CFO have concluded that as of December 31, 2025, our disclosure controls and procedures were effective.

Industry Context

StockSavvy.ai notes that the gene therapy sector remains highly competitive and capital-intensive, with significant regulatory hurdles, particularly for novel treatments targeting rare diseases. uniQure's experience with the FDA's feedback on AMT-130 highlights the evolving and stringent regulatory landscape for gene therapies, where even promising early-stage data may not suffice for accelerated approval without robust, prospectively designed controlled trials. The company's strategic shift to outsource manufacturing and streamline operations reflects a broader industry trend towards optimizing cost structures and focusing on core R&D, especially for companies with multiple clinical-stage assets. The ongoing class action lawsuit underscores the increased scrutiny and potential investor sensitivity to clinical trial outcomes and regulatory communications in this high-risk, high-reward field.

Comparison to Industry Standards

• The FDA's recommendation for a prospective, randomized, double-blind, sham surgery-controlled study for AMT-130 aligns with the highest industry standards for demonstrating efficacy and safety, particularly for novel gene therapies in neurodegenerative diseases. This is a more rigorous standard than relying on external controls, which some gene therapy companies have attempted for rare indications.
• The pause in dosing for AMT-191 due to liver enzyme elevations, and for AMT-162 due to a dose-limiting toxicity, reflects common safety challenges in gene therapy development, similar to those encountered by other companies in the field, such as those developing AAV-based therapies for liver or neurological conditions, where vector-related toxicities or immune responses can occur.
• uniQure's strategy of seeking Breakthrough Therapy, RMAT, Orphan Drug, and Fast Track designations for its candidates is standard practice for companies developing therapies for serious, unmet medical needs, aiming to expedite development and review, as seen with other gene therapy developers like Sarepta Therapeutics or Novartis Gene Therapies.
• The company's financial performance, with continued net losses and reliance on equity financing, is typical for a biotechnology company in the R&D phase, especially one advancing multiple gene therapy candidates. The capital raises in 2025 are consistent with the significant funding requirements for clinical development in this industry.

Corporate Governance

Legal Proceedings

• On February 10, 2026, a class action complaint, Christopher Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed in the U.S. District Court for the Southern District of New York.
• The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
• The putative class of investors purchased or acquired ordinary shares between September 24, 2025, and October 31, 2025.
• Plaintiff seeks damages for alleged false and misleading misstatements and omissions regarding the Phase I/II study of AMT-130 and the timing of its potential BLA filing.
• The company intends to vigorously defend against the claims.
• The outcome of the class action litigation and the range of possible losses are currently unpredictable and not reasonably estimable.

Stakeholder Impact

• **Shareholders:** Significant uncertainty and potential negative impact on share price due to FDA's rejection of current AMT-130 data for BLA submission and the need for further, more extensive clinical trials. Dilution risk from recent and potential future equity raises. Class action lawsuit adds legal and financial risk.
• **Patients (Huntington's Disease):** Potential significant delays in access to AMT-130, a promising gene therapy, due to extended clinical trial requirements.
• **Patients (Fabry Disease, SOD1-ALS):** Delays in development of AMT-191 and AMT-162 due to safety concerns and clinical pauses, impacting future treatment options.
• **Employees:** Workforce reductions (approximately 65% or 300 roles) in 2024 due to restructuring efforts, impacting morale and potentially increasing workload for remaining staff. Competition for qualified personnel remains intense.
• **Creditors (Hercules Capital):** Access to additional loan tranches is contingent on BLA approval of AMT-130, introducing risk to future funding availability if regulatory milestones are not met.
• **CSL Behring (HEMGENIX partner):** Continued reliance on Genezen for manufacturing HEMGENIX, with uniQure remaining contractually obligated for supply, potentially exposing uniQure to liabilities if Genezen fails to perform.
• **Genezen (Manufacturing partner):** Benefits from the acquisition of uniQure's Lexington facility and commercial manufacturing activities, but also assumes responsibility for HEMGENIX supply and uniQure's investigational programs, facing potential capacity and compliance challenges.

Next Steps

• Continue engaging with the FDA regarding Phase III development considerations for AMT-130.
• Request a Type B meeting with the FDA in the second quarter of 2026 to further discuss potential study design approaches for AMT-130.
• Continue to collect and evaluate data from the five patients dosed in the EPISOD1 trial for AMT-162.
• Further evaluate asymptomatic Grade 3 liver enzyme elevations in AMT-191 midand high-dose cohorts before resuming dosing.
• File definitive Proxy Statement for the 2026 Annual Meeting of Shareholders no later than April 30, 2026.
• Potentially draw down additional tranches of the Hercules loan facility, subject to BLA approval of AMT-130 and Hercules' approval.
• Potentially utilize the at-the-market (ATM) offering program for additional equity financing.

Key Dates

Recommendation

The FDA's rejection of uniQure's current AMT-130 data for BLA submission and the strong recommendation for a new, extensive Phase III trial represent a significant setback for the company's lead asset, introducing substantial delays and increased costs. This negative regulatory development is a major concern. However, the company has a strong cash position ($622.5 million) following recent capital raises, which provides runway into H2 2029, and other pipeline candidates (AMT-260, AMT-191) are progressing, albeit with some clinical pauses. The long-term potential of gene therapies for rare diseases remains, but the immediate future for AMT-130 is now much longer and more uncertain. A 'hold' recommendation reflects the significant downside risk from the FDA's decision, balanced by the company's financial liquidity and the potential, albeit delayed, of its broader pipeline. Investors should await further clarity on the revised AMT-130 development plan and the outcomes of other clinical programs before making new investment decisions.

Keywords

Gene Therapy, Huntington's Disease, AMT-130, FDA, Biologics License Application, Clinical Trials, Rare Diseases, Neurodegenerative Disorders, Fabry Disease, AMT-191, Temporal Lobe Epilepsy, AMT-260, ALS, SOD1-ALS, AMT-162, Biotechnology, Pharmaceutical, SEC Filing, Financial Results, Capital Raise, Regulatory Approval, Orphan Drug, Breakthrough Therapy, RMAT, Drug Development, Manufacturing, Intellectual Property, Corporate Governance